These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30945322)

  • 21. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
    BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
    Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
    Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
    BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
    Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies.
    Atagi S; Goto K; Seto T; Yamamoto N; Tamura T; Tajima K; Inagaki N
    Future Oncol; 2016 Sep; 12(18):2117-26. PubMed ID: 27267081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
    Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
    Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
    Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?].
    Hureaux J; Couturier O; Lacœuille F; Bouchet F; Chouaïd C; Saulnier P; Urban T;
    Rev Mal Respir; 2016 Nov; 33(9):817-823. PubMed ID: 27257103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erlotinib in non-small-cell lung cancer.
    Gridelli C; Rossi A; Maione P; Colantuoni G; Del Gaizo F; Ferrara C; Nicolella D; Guerriero C
    Expert Opin Pharmacother; 2007 Oct; 8(15):2579-92. PubMed ID: 17931092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.
    Lankheet NA; Schaake EE; Burgers SA; van Pel R; Beijnen JH; Huitema AD; Klomp H;
    Clin Lung Cancer; 2015 Jul; 16(4):320-4. PubMed ID: 25682545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.